SMOORE Launches Real-Time Monitoring Study on Nicotine Addiction

Jul.07.2022
SMOORE Launches Real-Time Monitoring Study on Nicotine Addiction
The world's largest e-cigarette manufacturer, SMOORE, partners with SIAT to study nicotine addiction and reduce nicotine levels in e-cigarettes.

The world's largest electronic cigarette manufacturer, SMOORE, has announced the launch of the world's first real-time monitoring research project on nicotine addiction.


The vaporization process between e-cigarettes and combustible cigarettes is vastly different, resulting in distinct physical and chemical properties obtained from vaporization and tobacco combustion, respectively.


Electronic cigarette company, SMOORE, has partnered with the Shenzhen Institute of Advanced Technology (SIAT) to undertake a new research project aimed at exploring ways to significantly reduce the nicotine strength in electronic cigarette products and ultimately lower it to non-addictive levels.


Under the direction of Nobel laureate Dr. Erwin Neher, the Neher Laboratory for Neural Plasticity in Shenzhen is the sixth laboratory in Shenzhen named after a Nobel laureate and the first dedicated to neuroscience. The laboratory focuses on researching the human brain and aims to better understand the mechanisms behind diseases and addictions through the use of the latest advanced techniques in modern neuroscience.


This joint study will investigate the secretion and metabolism of dopamine in the brains of animals, and use the data gathered to simulate the human brain state when nicotine is consumed. The laboratory will conduct controlled experiments by exposing test subjects to aerosol environments created by FEELM vaporization and combustion of tobacco.


The project aims to reduce the nicotine intake and subsequent dependence in adult e-cigarette users. This study will also assist SMOORE's research and development team in enhancing the design of e-cigarette devices by improving efficiency through modifying heating elements and atomizers to enhance the vaping experience.


Researchers involved in the project will monitor the aerosolization of e-liquid to gain a better understanding of nicotine absorption, distribution, metabolism in the human body. Additionally, the study will investigate how nicotine is absorbed by different organs to reveal the sensory satisfaction of e-cigarettes.


Dr. Xiong Yuming, Vice President of SMOORE Shenzhen Institute of Basic Research, stated that...


The process of vaporization between electronic cigarettes and combustible cigarettes is vastly different. Therefore, the physical and chemical properties obtained from vaporization and tobacco burning are also completely different. Our study focuses on the potential mechanisms of vaporization and tobacco burning, with the aim of exploring the delivery and absorption of nicotine to reduce the impact of these products on health.


This project is being supported by Southwest University in Chongqing, China. A phased report is expected to be released in the second half of 2022, which will outline the different effects of nicotine on the brain in electronic cigarettes and combustible tobacco products. This joint study on nicotine dependency aims to put an end to global nicotine addiction. Looking towards the future, FEELM aims to provide products that do not lead to nicotine dependency by reducing nicotine levels as close to zero as possible without compromising satisfaction.


This article is a compilation of third-party information, intended for educational and informational purposes only. The copyright for the compiled information belongs to the original media and authors. If there are any copyright infringements, please contact us for removal.



Disclaimer

This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.

Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.

The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.

This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.

 

Copyright Notice

This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.

No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.

For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.

 

AI-Assisted Translation and Editing Notice

Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.

Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.

JTI Makes Third Bet on South Korea as Ploom AURA Enters a Market Dominated by lil and IQOS
JTI Makes Third Bet on South Korea as Ploom AURA Enters a Market Dominated by lil and IQOS
Japan Tobacco International is stepping up its heated tobacco push in South Korea with Ploom AURA. Since its official launch in April 2026, the device's limited First Edition and Glacier White version have sold out, while distribution has expanded across Seoul, Incheon, Gyeonggi Province and airport duty-free channels. The rollout marks JTI's third major attempt to build a stronger heated tobacco position in South Korea, following Ploom TECH in 2019 and Ploom X Advanced in 2024. At the group level, JT plans to invest about ¥800 billion, approximately $5 billion, in reduced-risk products from 2026 through 2028, with heated products and Ploom identified as its primary investment priority.
Aug.14
JAMA Issues First U.S. Clinical Guidance on Vaping for Smoking Cessation, Urging Complete Switch From Cigarettes
JAMA Issues First U.S. Clinical Guidance on Vaping for Smoking Cessation, Urging Complete Switch From Cigarettes
JAMA has published a Special Communication offering systematic recommendations for U.S.-based clinicians on the use of nicotine e-cigarettes in adult smoking cessation. Developed by the Harm Reduction Workgroup of the Society for Research on Nicotine and Tobacco’s Treatment Research Network, the paper recommends including e-cigarettes alongside FDA-approved cessation medications in risk-benefit discussions. It cites high-certainty evidence that nicotine e-cigarettes achieve higher quit rates than nicotine replacement therapy and evidence suggesting efficacy comparable to highly effective medications such as varenicline and cytisine. For adults who choose vaping to quit, the authors recommend FDA-authorized products, sufficient nicotine delivery and a rapid, complete transition away from cigarettes rather than prolonged dual use.
Aug.13
Russia’s Vape Device Labeling Regime Enters Force: Registration Starts in September, Mandatory Coding in December
Russia’s Vape Device Labeling Regime Enters Force: Registration Starts in September, Mandatory Coding in December
Russia's digital labeling regime for reusable e-cigarettes and similar personal vaping devices entered its first mandatory phase in September 2026. From September 1, manufacturers, importers and other market participants must register with the national Chestny ZNAK tracking system. From December 1, newly manufactured and imported covered devices will be required to carry digital identification codes and be reported as entering circulation. Russia has also issued new operational guidance for imports, marking the transition from a voluntary pilot to phased mandatory implementation.
Sep.15
FDA Authorizes JUUL2, Cites Adult Switching Amid Efforts to Speed PMTA Reviews
FDA Authorizes JUUL2, Cites Adult Switching Amid Efforts to Speed PMTA Reviews
The FDA authorized the JUUL2 device and tobacco- and menthol-flavored pods on Aug. 28, bringing the number of authorized e-cigarette products to 48. The agency highlighted complete switching among adult smokers, with six-week switching rates reaching 28.4%–49.3% for the menthol pod. The decision comes as FDA works to speed PMTA reviews, reduce application backlogs and expand authorized e-cigarette and nicotine-pouch products while maintaining enforcement priorities for unauthorized products.
Regulations
Aug.29
BAT UK Director Tolga Kilic Says Illicit Nicotine Market Squeezes Legal Retailers Amid Rising Compliance Costs
BAT UK Director Tolga Kilic Says Illicit Nicotine Market Squeezes Legal Retailers Amid Rising Compliance Costs
UK retail publication Grocery Trader has published a viewpoint article from Tolga Kilic, Commercial Director for BAT UK & Ireland, discussing the impact of illicit nicotine products on legitimate retail channels. Kilic said illegal vapes and other illicit nicotine products create competitive pressure for compliant retailers and called for stronger market controls and supply-chain oversight. The comments come as the UK advances policies including the disposable vape ban and Vaping Products Duty, creating a more complex operating environment for legal vape retailers.
Jul.28
Charlie’s Says 30 PACHA Vape SKUs Tentatively Identified for FDA’s Non-Priority Enforcement Public List
Charlie’s Says 30 PACHA Vape SKUs Tentatively Identified for FDA’s Non-Priority Enforcement Public List
Charlie’s Holdings said the U.S. Food and Drug Administration notified the company on June 23, 2026, that 30 PACHA vape SKUs with submitted PMTAs had been tentatively identified for inclusion on a planned public-facing FDA webpage. Under enforcement guidance issued by FDA in May, the webpage is intended to identify certain unauthorized products for which the agency generally does not intend to prioritize enforcement of premarket authorization requirements. Charlie’s disclosed the development alongside second-quarter revenue of $3.8 million, up 116% year over year.
Aug.25